Interesting news, and confirms that the appetite by big pharma remains if the treatment regime appears to be a winner.
"AstraZeneca will also pay a non-transferable contingent value right of $3 per share, taking the combined transaction value to about $2.4 billion."
IFF CU6 is valued at US$2.4 billion = $14.00 / share = 5.2 times current price. My conclusion is that CU6 remains exceedingly cheap notwithstanding there's quite a way to go through the various FDA trials.
Research/Valuation, page-232
-
- There are more pages in this discussion • 308 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.46 |
Change
0.090(1.41%) |
Mkt cap ! $2.013B | |||
| Open | High | Low | Value | Volume |
| $6.40 | $6.50 | $6.13 | $10.02M | 1.580M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3329 | $6.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.50 | 45351 | 7 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |